Zobrazeno 1 - 10
of 17
pro vyhledávání: '"W H, Barr"'
Autor:
D Y, Mitchell, W H, Barr, R A, Eusebio, K A, Stevens, F P, Duke, D A, Russell, J D, Nesbitt, J H, Powell, G A, Thompson
Publikováno v:
Pharmaceutical research. 18(2)
To determine the pharmacokinetics and absolute bioavailability of risedronate after single-dose oral administration of 30 mg risedronate as a tablet and an aqueous solution, and 0.3 mg risedronate as an intravenous infusion.This study was a randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e13304f1c2681e0947473c712842b94c
https://pubmed.ncbi.nlm.nih.gov/11405286
https://pubmed.ncbi.nlm.nih.gov/11405286
Publikováno v:
Pharmaceutical research. 15(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3e0e493e63420da0b76418a4223955c2
https://pubmed.ncbi.nlm.nih.gov/9647365
https://pubmed.ncbi.nlm.nih.gov/9647365
Autor:
W H, Barr, R, Colucci, E, Radwanski, N, Zampaglione, D, Cutler, C C, Lin, M, Elliott, M B, Affrime
Publikováno v:
Journal of chemotherapy (Florence, Italy). 7
Isepamicin is a new aminoglycoside that has activity against many bacteria resistant to other aminoglycosides. The pharmacokinetics of isepamicin have been characterized in neonatal, pediatric, adult, elderly and renally impaired human populations as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dac38abf517f18cff84d489f71fd8705
https://pubmed.ncbi.nlm.nih.gov/8622111
https://pubmed.ncbi.nlm.nih.gov/8622111
Publikováno v:
Pharmaceutical research. 11(3)
The absorption of benazepril-HCl (BZPH), an orally active angiotensin-converting enzyme (ACE) inhibitor, in various regions of the gastrointestinal (GI) tract was investigated using an intestinal intubation technique. Thirteen subjects completed this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::633a97708e34c38567a031b976e3521f
https://pubmed.ncbi.nlm.nih.gov/8008712
https://pubmed.ncbi.nlm.nih.gov/8008712
Autor:
P H, Hsyu, J F, Pritchard, H P, Bozigian, T L, Lloyd, R H, Griffin, R, Shamburek, G, Krishna, W H, Barr
Publikováno v:
Pharmaceutical research. 11(1)
Ondansetron, an antagonist of the serotonin type 3 (5-HT3) receptor, is indicated for the treatment of chemotherapy-induced emesis. This study compares the pharmacokinetics, especially the bioavailability, of an ondansetron 8-mg solution when adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::26f72e616382491aebea951df26cd61b
https://pubmed.ncbi.nlm.nih.gov/8140047
https://pubmed.ncbi.nlm.nih.gov/8140047
Publikováno v:
International journal of clinical pharmacology, therapy, and toxicology. 30(10)
Plasma digoxin level is at best an indirect measure of pharmacological response to digoxin in patients being treated for congestive heart failure. Systolic time interval (STI) measurement reflecting left ventricular function at the physiological site
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30937f89a11406cb54cdedece794d477
https://pubmed.ncbi.nlm.nih.gov/1446955
https://pubmed.ncbi.nlm.nih.gov/1446955
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 257(1)
Despite the great attention given to the pharmacological actions of cocaine in recent years, the mechanisms leading to acute intoxication and related deaths after cocaine smoking have not been fully elucidated. The present study was therefore underta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13af779a5512d037fba0ed6a172eee10
https://pubmed.ncbi.nlm.nih.gov/2019993
https://pubmed.ncbi.nlm.nih.gov/2019993
Autor:
Virginia D. Schmith, W. H. Barr, George E. Dukes, S. Coots, Dennis Kelleher, Malcolm A. Young, A. Agyemang, W. Garnett, G. Sanderlin
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P49-P49
Background To characterize the PK/PD of alvimopan and its active metabolite (ADL 08–0011) in CC patients. Method Twenty females/three males with CC received placebo or 3 mg alvimopan (a peripherally-acting μ-opioid antagonist) BID for 7 days in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9014595e9e1bc3553cf52f1bcd0f2793
https://doi.org/10.1016/j.clpt.2004.12.080
https://doi.org/10.1016/j.clpt.2004.12.080
Publikováno v:
Clinical pharmacy. 4(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fdec6694601d73b19c57b6260d819a57
https://pubmed.ncbi.nlm.nih.gov/4006397
https://pubmed.ncbi.nlm.nih.gov/4006397
Publikováno v:
Clinical pharmacy. 5(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::190de20127533844b540bf77fd47f4cb
https://pubmed.ncbi.nlm.nih.gov/3948487
https://pubmed.ncbi.nlm.nih.gov/3948487